Transforming growth factor‐β1 inhibits interleukin‐1β‐induced expression of inflammatory genes and Cathepsin S activity in human vascular smooth muscle cells. (16th March 2021)
- Record Type:
- Journal Article
- Title:
- Transforming growth factor‐β1 inhibits interleukin‐1β‐induced expression of inflammatory genes and Cathepsin S activity in human vascular smooth muscle cells. (16th March 2021)
- Main Title:
- Transforming growth factor‐β1 inhibits interleukin‐1β‐induced expression of inflammatory genes and Cathepsin S activity in human vascular smooth muscle cells
- Authors:
- Dhaouadi, Nedra
Nehme, Ali
Faour, Wissam H.
Feugier, Patrick
Cerutti, Catherine
Kacem, Kamel
Eid, Ali H.
Li, Jacques‐Yuan
Zibara, Kazem - Abstract:
- Abstract: Objective and design: This study investigated the opposite mechanisms by which IL‐1β and TGF‐β1 modulated the inflammatory and migratory phenotypes in cultured human intimal vascular smooth muscle cells vSMCs. Materials and treatment: Primary human vSMCs, obtained from twelve hypertensive patients who underwent carotid endarterectomy, were incubated for 24 hours with either 40 pM TGF‐β1, or 1 nmol/L IL‐1β, or their combination in presence or absence of anti‐TGF‐β neutralizing antibody. Methods: The expression levels of matrix metalloproteases and their inhibitors, and the elastolytic enzyme cathepsin S (CTSS) and its inhibitor cystatin C were evaluated with RT‐PCR. CTSS activity was measured by fluorometry. Results: TGF‐β1 reversed IL‐1β‐induced expression of iNOS, CXCL6, IL1R1, MMP12, and CTSS, while upregulated TIMP2 expression. Furthermore, anti‐TGF‐β neutralizing antibody abrogated TGF‐β effects. Combination with IL‐1β and TGF‐β1 induced the expression of IL1α, IL1β, IL1R1, and CTSS, but suppressed CST3 expression. CTSS expression in the combination treatment was higher than that of cells treated with anti‐TGF‐β antibodies alone. Moreover, IL‐1β‐induced CTSS enzymatic activity was reduced when human vSMCs were co‐treated with TGF‐β, whereas this reduction was abrogated by anti‐TGF‐β neutralizing antibody. Conclusion: TGF‐β1 abrogated IL‐1β‐induced expression of inflammatory genes and elastolytic activity in cultured human vSMCs. Thus, TGF‐β1 can play a crucialAbstract: Objective and design: This study investigated the opposite mechanisms by which IL‐1β and TGF‐β1 modulated the inflammatory and migratory phenotypes in cultured human intimal vascular smooth muscle cells vSMCs. Materials and treatment: Primary human vSMCs, obtained from twelve hypertensive patients who underwent carotid endarterectomy, were incubated for 24 hours with either 40 pM TGF‐β1, or 1 nmol/L IL‐1β, or their combination in presence or absence of anti‐TGF‐β neutralizing antibody. Methods: The expression levels of matrix metalloproteases and their inhibitors, and the elastolytic enzyme cathepsin S (CTSS) and its inhibitor cystatin C were evaluated with RT‐PCR. CTSS activity was measured by fluorometry. Results: TGF‐β1 reversed IL‐1β‐induced expression of iNOS, CXCL6, IL1R1, MMP12, and CTSS, while upregulated TIMP2 expression. Furthermore, anti‐TGF‐β neutralizing antibody abrogated TGF‐β effects. Combination with IL‐1β and TGF‐β1 induced the expression of IL1α, IL1β, IL1R1, and CTSS, but suppressed CST3 expression. CTSS expression in the combination treatment was higher than that of cells treated with anti‐TGF‐β antibodies alone. Moreover, IL‐1β‐induced CTSS enzymatic activity was reduced when human vSMCs were co‐treated with TGF‐β, whereas this reduction was abrogated by anti‐TGF‐β neutralizing antibody. Conclusion: TGF‐β1 abrogated IL‐1β‐induced expression of inflammatory genes and elastolytic activity in cultured human vSMCs. Thus, TGF‐β1 can play a crucial role in impairing IL‐1β‐induced vascular inflammation and damage involved in the etiology of cardiovascular diseases. … (more)
- Is Part Of:
- Fundamental & clinical pharmacology. Volume 35:Number 6(2021)
- Journal:
- Fundamental & clinical pharmacology
- Issue:
- Volume 35:Number 6(2021)
- Issue Display:
- Volume 35, Issue 6 (2021)
- Year:
- 2021
- Volume:
- 35
- Issue:
- 6
- Issue Sort Value:
- 2021-0035-0006-0000
- Page Start:
- 979
- Page End:
- 988
- Publication Date:
- 2021-03-16
- Subjects:
- atherosclerosis -- elastolytic activity -- inflammatory phenotype -- interleukin‐1 -- transforming growth factor‐β1 -- vascular smooth muscle cells
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=fcp ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1472-8206 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/fcp.12666 ↗
- Languages:
- English
- ISSNs:
- 0767-3981
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4056.033000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 19828.xml